Update on aquaporin-4 antibody detection: the early diagnosis of neuromyelitis optica spectrum disorders

Xiao-Fang Ye,Zheng-Ping Huang,Mi-Mi Li,Shu-Fen Liu,Wan-Li Huang,Abdullahi Mukhtar Sheik Hamud,Li-Chao Ye,Lin-Yi Li,Shu-Juan Wu,Jian-Long Zhuang,Yan-Hong Chen,Xiang-Rong Chen,Shu Lin,Xiao-Feng Wei,Chun-Nuan Chen
DOI: https://doi.org/10.1016/j.msard.2024.105803
2024-08-05
Abstract:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune-mediated primary inflammatory myelinopathy of the central nervous system that primarily affects the optic nerve and spinal cord. The aquaporin 4 antibody (AQP4-Ab) is a specific autoantibody marker for NMOSD. Most patients with NMOSD are seropositive for AQP4-Ab, thus aiding physicians in identifying ways to treat NMOSD. AQP4-Ab has been tested in many clinical and laboratory studies, demonstrating effectiveness in diagnosing NMOSD. Recently, novel assays have been developed for the rapid and accurate detection of AQP4-Ab, providing further guidance for the diagnosis and treatment of NMOSD. This article summarizes the importance of rapid and accurate diagnosis for treating NMOSD based on a review of the latest relevant literature. We discussed current challenges and methods for improvement to offer new ideas for exploring rapid and accurate AQP4-Ab detection methods, aiming for early diagnosis of NMOSD.
What problem does this paper attempt to address?